HOME >> BIOLOGY >> NEWS
Bigger betas are better Protein found to provide pancreatic cells with protection against diabetes

(Philadelphia, PA) While studying the proteins in pancreatic beta (β) cells the cells that produce insulin researchers at the University of Pennsylvania Medical Center discovered how the protein enzyme Akt1 can cause mice β cells to grow larger and produce more insulin. Their findings, published in this months Nature Medicine, have direct implications for the current need to increase the number of human pancreatic cells available for transplant to diabetic patients.

"The mice bred to produce excess Akt1 protein were more tolerant of glucose and more resistant to diabetes in fact, we simply could not give them diabetes when we tried," said Morris J. Birnbaum, MD, PhD, associate director of the Penn Diabetes Center in the Penn Departments of Medicine & Cell and Molecular Biology and an investigator in the Howard Hughes Medical Institute. "The increase in Akt1 directly leads to an increase in the size, amount, and total production of insulin by β cells."

In the United States, diabetes is the seventh leading cause of death and currently effects over 15 million people. Medical science recognizes two forms of diabetes. Type 1 diabetes results from the immune systems destruction of pancreatic β cells. Type 2 diabetes results when the body cannot either produce enough insulin or properly use the insulin it does produce. Without insulin, the body cannot utilize glucose blood sugar which can lead to a variety of debilitating illnesses, including heart disease, blindness, and kidney failure.

Recently, surgeons have met with success in treating the disorder by transplanting clusters of pancreatic cells, called islets, into diabetic patients. Transplanted islets, which include β cells, have been shown to reestablish the production of insulin in the pancreas. Unfortunately, the demand for islets far outweighs the supply.

"What makes our findings so interesting, clinically, is the potential to enlarge our pool of β cells f
'"/>

Contact: Greg Lester
lesterg@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
18-Oct-2001


Page: 1 2

Related biology news :

1. Bigger isnt always better--especially if youre a rodent
2. Spray Forming Aerospace Alloys For Bigger Aircraft
3. New Sunspot Cycle To Be Bigger Than Average
4. Mapping The Way To A Bigger Prawn
5. Bigger Biology Tackled Through Keyboards
6. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
7. Microbes eat their way to better concrete
8. Computer database being developed at Temple will allow for better inventory of chemicals
9. New and better drugs for tuberculosis goal of UH professor
10. Ants protect plants better when jacked up on nectar
11. The blind really do hear better

Post Your Comments:
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary commercial focus on ... has been granted a Type C meeting with the ... meeting will be held in February 2015.  During this ...
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
(Date:12/13/2014)... and Virgin Unite Canada, the non-profit foundation of the Virgin ... Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... Centre to announce the new partnership, which includes the development ... $1 million in seed capital provided by Virgin Unite Canada ... Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
Cached News: